Chengdu Purevalley Medical Technology

Chengdu Purevalley Medical Technology is a specialized medical device company focused on the development of transcatheter solutions for structural heart diseases. Based in Chengdu, China, the company was established in 2020 to address unmet needs in the treatment of valvular heart conditions through minimally invasive technologies. Its primary product pipeline includes the Pure-Alpha Transcatheter Aortic Valve Implantation (TAVI) system and the Pure-Beta Transcatheter Mitral Valve Replacement (TMVR) system. The company utilizes advanced tissue engineering and delivery system designs to enhance the safety and efficacy of heart valve replacements. Purevalley is supported by leading venture capital firms such as CD Capital and Northern Light Venture Capital. By collaborating with top-tier clinical institutions, the company aims to provide high-quality, accessible cardiovascular interventions for patients globally.